Frank M Sacks1. 1. Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism RECENT FINDINGS: ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance. Normolipidemia is sustained by hepatic secretion of VLDL and IDL subspecies that contain both apoE and apoC-III (VLDL E+C-III+). Most of this VLDL E+C-III+ is speedily lipolyzed, reduced in apoC-III content, and cleared from the circulation as apoE containing dense VLDL, IDL, and light LDL. In contrast, in hypertriglyceridemia, most VLDL is secreted with apoC-III but without apoE, and so it is not cleared until it loses apoC-III during lipolysis to dense LDL. In normolipidemia, the liver also secretes IDL and large and medium-size LDL, whereas in hypertriglyceridemia, the liver secretes more dense LDL with and without apoC-III. These pathways establish the hypertriglyceridemic phenotype and link it metabolically to dense LDL. Dietary carbohydrate compared with unsaturated fat suppresses metabolic pathways mediated by apoE that are qualitatively similar to those suppressed in hypertriglyceridemia. SUMMARY: The opposing actions of apoC-III and apoE on subspecies of VLDL and LDL, and the direct secretion of LDL in several sizes, establish much of the basic structure of human apoB lipoprotein metabolism in normal and hypertriglyceridemic humans.
PURPOSE OF REVIEW: To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism RECENT FINDINGS:ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance. Normolipidemia is sustained by hepatic secretion of VLDL and IDL subspecies that contain both apoE and apoC-III (VLDL E+C-III+). Most of this VLDL E+C-III+ is speedily lipolyzed, reduced in apoC-III content, and cleared from the circulation as apoE containing dense VLDL, IDL, and light LDL. In contrast, in hypertriglyceridemia, most VLDL is secreted with apoC-III but without apoE, and so it is not cleared until it loses apoC-III during lipolysis to dense LDL. In normolipidemia, the liver also secretes IDL and large and medium-size LDL, whereas in hypertriglyceridemia, the liver secretes more dense LDL with and without apoC-III. These pathways establish the hypertriglyceridemic phenotype and link it metabolically to dense LDL. Dietary carbohydrate compared with unsaturated fat suppresses metabolic pathways mediated by apoE that are qualitatively similar to those suppressed in hypertriglyceridemia. SUMMARY: The opposing actions of apoC-III and apoE on subspecies of VLDL and LDL, and the direct secretion of LDL in several sizes, establish much of the basic structure of humanapoB lipoprotein metabolism in normal and hypertriglyceridemichumans.
Authors: Mark J Graham; Richard G Lee; Thomas A Bell; Wuxia Fu; Adam E Mullick; Veronica J Alexander; Walter Singleton; Nick Viney; Richard Geary; John Su; Brenda F Baker; Jennifer Burkey; Stanley T Crooke; Rosanne M Crooke Journal: Circ Res Date: 2013-03-29 Impact factor: 17.367
Authors: Shaila P Handattu; Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Vinod K Mishra; Geeta Datta; G M Anantharamaiah Journal: Atherosclerosis Date: 2012-11-02 Impact factor: 5.162
Authors: Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao Journal: J Lipid Res Date: 2010-01 Impact factor: 5.922
Authors: Carlos O Mendivil; Chunyu Zheng; Jeremy Furtado; Julian Lel; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2009-11-12 Impact factor: 8.311
Authors: Avani A Pendse; Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Nobuyo Maeda Journal: J Lipid Res Date: 2008-12-05 Impact factor: 5.922
Authors: Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén Journal: Diabetes Date: 2009-06-05 Impact factor: 9.461
Authors: Sarah A Aroner; Jeremy D Furtado; Frank M Sacks; Michael Y Tsai; Kenneth J Mukamal; Robyn L McClelland; Majken K Jensen Journal: Diabetologia Date: 2019-04-04 Impact factor: 10.122
Authors: Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt Journal: J Clin Invest Date: 2019-07-11 Impact factor: 14.808
Authors: Gissette Reyes-Soffer; Carol Sztalryd; Richard B Horenstein; Stephen Holleran; Anastasiya Matveyenko; Tiffany Thomas; Renu Nandakumar; Colleen Ngai; Wahida Karmally; Henry N Ginsberg; Rajasekhar Ramakrishnan; Toni I Pollin Journal: Arterioscler Thromb Vasc Biol Date: 2019-01 Impact factor: 8.311
Authors: Majken K Jensen; Sarah A Aroner; Kenneth J Mukamal; Jeremy D Furtado; Wendy S Post; Michael Y Tsai; Anne Tjønneland; Joseph F Polak; Eric B Rimm; Kim Overvad; Robyn L McClelland; Frank M Sacks Journal: Circulation Date: 2017-11-21 Impact factor: 29.690
Authors: Allyson M Morton; Manja Koch; Carlos O Mendivil; Jeremy D Furtado; Anne Tjønneland; Kim Overvad; Liyun Wang; Majken K Jensen; Frank M Sacks Journal: JCI Insight Date: 2018-02-22
Authors: Andrew A Butler; Jinsong Zhang; Candice A Price; Joseph R Stevens; James L Graham; Kimber L Stanhope; Sarah King; Ronald M Krauss; Andrew A Bremer; Peter J Havel Journal: J Biol Chem Date: 2019-04-15 Impact factor: 5.157
Authors: Julio Alejandro Lamprea-Montealegre; Natalie Staplin; William G Herrington; Richard Haynes; Jonathan Emberson; Colin Baigent; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2019-12-12 Impact factor: 8.237